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In 2013, the ﬁrst randomized clinical trial on faecal microbiota
transplantation (FMT) highlighted its clinical efﬁcacy in achieving
clinical cure for recurrent Clostridium difﬁcile infection (CDI) [1].
FMT has been integrated into European guidelines as a standard
for treatment of patients with multiple relapses of CDI [2].
Further studies have shown that encapsulation and storage of
faecal transplants at−80°Csimpliﬁes the procedure and improves
patient safety and acceptance [3,4]. Despite these advantages,
frozen, capsulized FMT (cFMT) has not been made available to
patients in Europe. As the ﬁrst European centre integrating cFMT
into clinical practice, we report on three patients.
All patients had a history of recurrent CDI, deﬁned as
more than three unformed bowel movements (UBM) in the
presence of a positive C. difﬁcile toxin A or B assay result, and
developed a further recurrence after treatment with metro-
nidazole, vancomycin and ﬁdaxomicin. Before administration
of donor faeces, patients received a bowel lavage with 3–4 LMicrobiol Infect 2015; 21: e82–e84
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with vancomycin or ﬁdaxomicin before cFMT varied, as it was
initiated at the discretion of the referring institutions. Donors
were healthy volunteers completing a screening-questionnaire
on transmittable infections and general medical history.
Donor faeces were screened according to established pro-
tocols [1]. Capsules were prepared as previously described
[3]. Each set of at least 30 capsules was produced from a
minimum of 50 g of donor faeces. Depending on the initial
weight and consistency of the donation, the number of
capsules produced varied slightly. During the ﬁrst 30 days
after cFMT, patients completed a bowel movement diary to
ensure adequate evaluation of response. A new episode of
diarrhoea was deﬁned as more than three UBM per day for at
least 2 consecutive days. The day of transplant was deﬁned as
day 0.
The ﬁrst patient was a 70-year-old female with signiﬁcant
weight loss from four episodes of recurrent CDI with diarrhoea
and abdominal cramps for 9 months. Her initial episode of CDI
had occurred after a course of prophylactic clindamycin upon
resection of melanocytic naevi. Before cFMT she was condi-
tioned with oral ﬁdaxomicin 200 mg twice daily. She received
cFMT on day 0 (30 capsules) and day 1 (six capsules). On day 2,
she reported a single UBM. Upon follow up at 2 months, she
reported no recurrence of CDI and substantial weight gain. In
addition to analysis of capsulized microbiota, the patient’s faecal
microbiome was analysed on day −1, at the end of days 1 and 2,
and on day 7 and day 31 using next-generation sequencing of
the variable bacterial V2–V4 and V6–V9 16S rDNA region [5].
Total DNA was isolated with the Maxwell 16 Instrument using
the Maxwell 16 Tissue LEV RNA Puriﬁcation Kit (Promega
Corporation, Madison, WI, USA) according to the manufac-
turer’s instructions. The sequence data obtained were
compared with available libraries and taxonomically aligned
using QIIME. Microbial diversity was estimated using the
Shannon diversity index. Taxonomic classiﬁcations were drawn
as block diagrams (Fig. 1).
The recipient’s faecal Shannon diversity index increased from
4.85 on day −1 to 6.1 on day 1 with the encapsulated micro-
biota displaying an index of 5.63. During the following mea-
surements on day 2, 7 and 31, the index remained stable with
values of 6.22, 5.95 and 5.87, respectively. Before cFMT, there
were only 8% of shared operational taxonomic units between
donor and recipient. This percentage changed to 16% on day 2,
39% on day 7 and 34% on day 31 (p < 0.01).
The second patient was an 86-year-old female nursing home
resident with three CDI recurrences after antibiotic treatment
for a urinary tract infection. At cFMT up to 10 UBM persisted
despite ongoing vancomycin treatment at 250 mg four timesious Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Faecal microbiota composition of capsulized faecal microbiota transplantation and patient samples on day −1, day 1, day 2, day 7 and day 31.
Block diagram of abundance at the species level. Operational taxonomic units (OTUs) were grouped into the appropriate species and plotted over
time.
CMI Letter to the Editor e83daily. She required parenteral nutrition and intravenous ﬂuid
replacement because of severe anorexia, abdominal cramping
and nausea. She received 30 capsules over two consecutive
days. Apart from initial difﬁculty swallowing, no adverse events
occurred. Her UBM decreased on day 2 and intravenous
nutrition and ﬂuids were stopped. At day 47 cure was
sustained.
The third patient was a 62-year-old female with ovarian
cancer diagnosed in 2013. After placement of double-j stents
for urinary retention, she had developed recurrent urinary
tract infections, and received corresponding antibiotic treat-
ments triggering CDI. After 6 months and a total of ﬁve epi-
sodes of recurrent CDI, she was referred for cFMT and
received 24 capsules on day 0 and six capsules on day 1 after
conditioning with oral vancomycin 500 mg four times daily. Mild
nausea was the only reported adverse event. End of diarrhoea
occurred on day 1. At day 30, cure was sustained. Of note, on
day 12 rigorous laxative treatment ended prolonged
obstipation.
Based on the results of these three patients, cFMT is now an
option in our CDI treatment path. To conﬁrm the clinical
efﬁcacy of this approach and assess its value in other in-
dications, e.g. primary treatment of severe CDI caused by
ribotype 027 or decolonization of patients carrying
carbapenemase-producing bacteria, randomized controlled
trials are needed.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyTransparency declarationMJGTV has served at the speakers’ bureau of Pﬁzer, Merck/MSD,
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